Efficacy of HIPEC as NACT and Postoperative Chemotherapy in the Treatment of Advanced-Stage Epithelial Ovarian Cancer
Last updated on July 2021Recruitment
- Recruitment Status
- Not yet recruiting
- Estimated Enrollment
- 184
Summary
- Conditions
- Epithelial Ovarian Cancer
- Fallopian Tube Cancer
- Primary Peritoneal Carcinoma
- Type
- Interventional
- Phase
- Phase 3
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentMasking: Single (Participant)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 70 years
- Gender
- Only males
Description
The current standard treatment for epithelial ovarian cancer, tubal cancer, and primary peritoneal cancer is maximal cytoreductive surgery followed by intravenous chemotherapy with or without intraperitoneal chemotherapy (IP). Recently, the organizations of SGO and ASCO recommended that women with a...
The current standard treatment for epithelial ovarian cancer, tubal cancer, and primary peritoneal cancer is maximal cytoreductive surgery followed by intravenous chemotherapy with or without intraperitoneal chemotherapy (IP). Recently, the organizations of SGO and ASCO recommended that women with a high perioperative risk profile or a low likelihood of achieving cytoreduction to < 1 cm of residual disease (ideally to novisible disease) should receive neoadjuvant chemotherapy. Hyperthermia promotes chemotherapy to penetrate deeper into the cancer tissue. Therefore, hyperthermic intraperitoneal chemotherapy (HIPEC) as neoadjuvant chemotherapy and postoperative chemotherapy after interval debulking surgery in the treatment of ovarian cancer could lead to higher response rate and better survival outcomes.
Tracking Information
- NCT #
- NCT03180177
- Collaborators
- Xiangya Hospital of Central South University
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
- Third Affiliated Hospital, Sun Yat-Sen University
- Henan Provincial People's Hospital
- Henan Cancer Hospital
- The Third Xiangya Hospital of Central South University
- Beijing Cancer Hospital
- Obstetrics & Gynecology Hospital of Fudan University
- Peking University People's Hospital
- Cancer Hospital of Guizhou Province
- Xinqiao Hospital of Chongqing
- Chongqing Cancer Institute
- Wuhan Union Hospital, China
- West China Second University Hospital
- RenJi Hospital
- Shandong Cancer Hospital and Institute
- The Third Affiliated Hospital of Guangzhou Medical University
- Chinese PLA General Hospital
- Southern Medical University, China
- Fourth Affiliated Hospital of Guangxi Medical University
- First Affiliated Hospital, Sun Yat-Sen University
- Wuhan University
- Hebei Medical University Fourth Hospital
- Tianjin Medical University Cancer Institute and Hospital
- Beijing Obstetrics and Gynecology Hospital
- The Second Hospital of Hebei Medical University
- Peking Union Medical College Hospital
- Investigators
- Study Director: Shuzhong Cui, M.D Affiliated Cancer Hospital & Institute of Guangzhou Medical University Study Director: Zhongqiu Lin, M.D Sun Yat-sen Memorial Hospital,Sun Yat-sen University
Get Well Soon